On Tuesday, Shares of Sirius XM Holdings Inc. (NASDAQ:SIRI), lost -0.38% to $3.94.
Sirius XM declared recently that it will broadcast Phish’s Magnaball Festival in Watkins Glen, NY, August 20 through August 23, on SiriusXM’s Jam On channel.
The live broadcast of the festival will comprise seven live Phish sets throughout the weekend. The broadcast will also comprise exclusive material from the band’s archives presented by Phish’s official archivist Kevin Shapiro.
The broadcast will air on Bunny Radio, a live, freeform radio station Phish creates on-site at their festivals. Bunny Radio will take over SiriusXM’s Jam On channel for the weekend-long festival.
Sirius XM Holdings Inc., through its auxiliaries, provides satellite radio services in the United States. The company broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, counting various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and local traffic reports for 22 metropolitan markets.
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR), declined -15.02% to $64.17, during its last trading session.
Esperion Therapeutics offered an update from the ETC-1002 (bempedoic acid) End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) last week. The FDA confirmed that LDL-C remains an acceptable clinical surrogate endpoint for the approval of an LDL-C lowering therapy such as ETC-1002 in patient populations who have a high unmet medical need, counting patients with heterozygous familial hypercholesterolemia (HeFH), or clinical atherosclerotic cardiovascular disease (ASCVD), who are already taking maximally tolerated statins yet require additional LDL-C reduction and where there is a positive benefit/risk ratio. Based on feedback from the FDA, approval of ETC-1002 in the HeFH and ASCVD patient populations will not require the completion of a cardiovascular outcomes trial (CVOT). The Company continues to plan and initiate a CVOT preceding to NDA filing to pursue broader label indications related to cardiovascular disease risk reduction.
Esperion remains on track to initiate the ETC-1002 Phase 3 development program by the end of 2015. The program will support a projected label indication for the use of ETC-1002, an oral, once-daily LDL-C lowering therapy, “as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH), or atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C.” About nine million patients in the U.S. fall into these two combined categories.
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.
Finally, Baxter International Inc. (NYSE:BAX), ended its last trade with -0.42% loss, and closed at $40.59.
Baxter International and Water Street Healthcare Partners declared the United States Food and Drug Administration (FDA) has approved CEFAZOLIN Injection in GALAXY Container (2 g/100 mL), which is Baxter’s flexible container that uses the company’s proprietary aseptic filling manufacturing processes. CEFAZOLIN injection is a cephalosporin antibacterial indicated for preoperative prophylaxis treatment. When used for preoperative prevention, it may reduce the incidence of certain postoperative infections for high-risk patients undergoing surgical procedures.
CEFAZOLIN injection has been on the FDA’s drug shortage list for more than one year due to high demand. Baxter anticipates launching CEFAZOLIN injection 2 gram frozen premix in its GALAXY container in the United States in the fourth quarter of 2015.
CEFAZOLIN injection 2 gram represents the first of nine molecules actively under development to provide healthcare providers needed injectable formulations of essential drugs frequently used in critical care settings through Baxter’s development partnership with Celerity Pharmaceuticals, LLC, a company of Water Street, a planned investor focused exclusively on the healthcare industry.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
